A balancing act for breast cancer? Everolimus for hormone receptor positive patients

Translational Cancer Research

Volumn 1, Issue 2, 2012, Pages 109-112

  Wheeler, Stephanie B ^a,b   Reeder Hayes, Katherine ^b,c   Meyer, Anne Marie ^b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; EXEMESTANE;

ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS;

EID: 84962781321     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2012.03.02     Document Type: Article

References (17)

1. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
2. Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003;(2):CD002747.
3. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7.
4. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91.
5. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010;22:169-76.
6. Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Semin Oncol 2006;33:S18-25.
7. Zaytseva YY, Valentino JD, Gulhati P, et al. mTOR inhibitors in cancer therapy. Cancer Lett 2012;319:1-7.
8. Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012;118:3014-25.
9. Treeck O, Wackwitz B, Haus U, et al. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006;102:292-9.
10. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6.
11. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-8.
12. Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009;27:3445-51.
13. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-8.
14. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-55.
15. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502.
16. Vermaat JS, Nijman IJ, Koudijs MJ, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res 2012;18:688-99.
17. Wang LE, Ma H, Hale KS, et al. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 2012;138:377-85.